These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15281320)

  • 1. Clonal development of bladder cancer and its relevance to the clinical potential of HLA antigen and TP53 based gene therapy.
    Nouri AM; Oliver RT; Nardgund VH
    Cancer Surv; 1998; 31():109-28. PubMed ID: 15281320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.
    Rini BI; Selk LM; Vogelzang NJ
    Clin Cancer Res; 1999 Oct; 5(10):2766-72. PubMed ID: 10537340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of bladder cancer: targets for diagnosis and therapy.
    Baffa R; Letko J; McClung C; LeNoir J; Vecchione A; Gomella LG
    J Exp Clin Cancer Res; 2006 Jun; 25(2):145-60. PubMed ID: 16918124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of surgery in the multimodality treatment of bladder cancer.
    Coptcoat MJ; Oliver RT
    Cancer Surv; 1998; 31():129-47. PubMed ID: 15281321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Kageshita T; Ishihara T; Campoli M; Ferrone S
    Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
    Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
    Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
    Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
    Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic HLA-B7-restricted peptides of hTRT.
    Cortez-Gonzalez X; Sidney J; Adotevi O; Sette A; Millard F; Lemonnier F; Langlade-Demoyen P; Zanetti M
    Int Immunol; 2006 Dec; 18(12):1707-18. PubMed ID: 17077179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease.
    Guzzo TJ; Rogers CG; Deng CY; Bivalacqua TJ; Palapattu GS; Bastian PJ; Eisenberger MA; Schoenberg MP; Gonzalgo ML
    BJU Int; 2008 Dec; 102(11):1539-43. PubMed ID: 18727617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.
    Loskog A; Ninalga C; Hedlund T; Alimohammadi M; Malmström PU; Tötterman TH
    Lab Anim; 2005 Oct; 39(4):384-93. PubMed ID: 16197705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Squamous change in bladder cancer and its relevance to understanding clonal evolution in development of bladder cancer.
    Baithun S; Daruwala P; Oliver RT
    Cancer Surv; 1998; 31():17-27. PubMed ID: 15281315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
    Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
    Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 gene mutations as an independent marker for urinary bladder cancer progression.
    Ecke TH; Sachs MD; Lenk SV; Loening SA; Schlechte HH
    Int J Mol Med; 2008 May; 21(5):655-61. PubMed ID: 18425359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
    Christoph F; Hinz S; Weikert S; Kempkensteffen C; Schostak M; Miller K; Schrader M
    Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the evolution of human metastatic bladder cancer.
    Nicholson BE; Frierson HF; Conaway MR; Seraj JM; Harding MA; Hampton GM; Theodorescu D
    Cancer Res; 2004 Nov; 64(21):7813-21. PubMed ID: 15520187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder cancer.
    Gwynn ES; Clark PE
    Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.